Table 2.

Overview of efficacy results

	Day 22	Day 35	Day 43	Day 50
Percent change in EASI from baseline, mean ± SD	−47.46 ± 22.775	−59.26 ± 37.646	−80.78 ± 15.076	−87.15 ± 13.396
Patients achieving EASI‐50, n (%)	7 (50.0)	11 (78.6)	13 (92.9)	13 (92.9)
Patients achieving EASI‐75, n (%)	0	6 (42.9)	10 (71.4)	11 (78.6)
Patients achieving EASI‐90, n (%)	0	1 (7.1)	5 (35.7)	7 (50.0)
Patients achieving IGA 0 or 1, n (%)	0	1 (7.1)	4 (28.6)	7 (50.0)
Percent change in AD affected body surface area from baseline, mean ± SD	−25.91 ± 29.182	−37.40 ± 52.202	−62.67 ± 23.553	−74.82 ± 24.170

Results were based on all observed values. N = 13 for all measurements except for Day 35 (n = 14). AD, atopic dermatitis; EASI, Eczema Area and Severity Index; EASI‐50, ≥ 50% reduction in EASI from baseline; EASI‐75, ≥ 75% reduction in EASI from baseline; EASI‐90, ≥ 90% reduction in EASI from baseline; IGA, Investigator's Global Assessment; SD, standard deviation.